2025 United Kingdom Antibody Protection Revenue Opportunities Report
Description
The 2025 United Kingdom Antibody Protection Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibody Protection by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in antibody protection in the UK include Abcam, Autolus Therapeutics, GSK (GlaxoSmithKline), and Amphista Therapeutics. Abcam, headquartered in Cambridge, is a leading producer and distributor of protein research tools, with a strong antibody services market presence and extensive R&D operations under the Danaher Corporation since 2023. Autolus, based in London, specializes in CAR-T cell therapies using engineered T-cells for targeted cancer treatment and has received FDA approval for its lead product obe-cel, signaling a major UK advancement in immuno-oncology.
GSK is a major pharmaceutical company focusing on immune system science and advanced technologies across several therapeutic areas including immunology, respiratory, and oncology, positioning it as a key player in antibody-related therapies in the UK. Amphista Therapeutics, from Cambridge, develops next-generation molecular glue therapies that promote targeted protein degradation for cancer and neurological disorders, with significant funding and collaboration deals, notably with Bristol Myers Squibb. Together, these companies reflect the UK's robust innovation and leadership in antibody protection and immuno-oncology research.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibody Protection by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in antibody protection in the UK include Abcam, Autolus Therapeutics, GSK (GlaxoSmithKline), and Amphista Therapeutics. Abcam, headquartered in Cambridge, is a leading producer and distributor of protein research tools, with a strong antibody services market presence and extensive R&D operations under the Danaher Corporation since 2023. Autolus, based in London, specializes in CAR-T cell therapies using engineered T-cells for targeted cancer treatment and has received FDA approval for its lead product obe-cel, signaling a major UK advancement in immuno-oncology.
GSK is a major pharmaceutical company focusing on immune system science and advanced technologies across several therapeutic areas including immunology, respiratory, and oncology, positioning it as a key player in antibody-related therapies in the UK. Amphista Therapeutics, from Cambridge, develops next-generation molecular glue therapies that promote targeted protein degradation for cancer and neurological disorders, with significant funding and collaboration deals, notably with Bristol Myers Squibb. Together, these companies reflect the UK's robust innovation and leadership in antibody protection and immuno-oncology research.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
